PMID- 32939195
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1450-1147 (Print)
IS  - 1607-3312 (Electronic)
IS  - 1450-1147 (Linking)
VI  - 19
IP  - 2
DP  - 2020 Apr-Jun
TI  - Comparison of (68)Ga-DOTA-NaI(3)-Octreotide/tyr(3)-octreotate positron emission 
      tomography/computed tomography and contrast-enhanced computed tomography in 
      localization of tumors in multiple endocrine neoplasia 1 syndrome.
PG  - 99-105
LID - 10.4103/wjnm.WJNM_24_19 [doi]
AB  - The optimum imaging modality for the screening of multiple endocrine neoplasia 
      type 1 (MEN1)-associated tumors is not well established. Here, we compare the 
      performance of contrast-enhanced CT (CECT) versus (68)Ga DOTA-NOC/TATE PET/CT in 
      MEN1 patients. The retrospective case record study is conducted at a tertiary 
      health-care center. Thirty-four patients, who have undergone both CECT and (68)Ga 
      DOTA-NOC/ TATE PET, were included in the analysis. CECT had higher per-lesion 
      sensitivity than (68)Ga DOTA-NOC/TATE PET/CT for the detection of parathyroid 
      lesions, (82.6% vs. 24.6%, P < 0.001). (68)Ga DOTA-NOC/TATE PET/CT had higher 
      per-lesion sensitivity than CECT for the detection of metastases (85% vs. 47.5%, 
      P < 0.001) and gastrinomas (90% vs. 10%, P = 0.003). When combined use of the two 
      imaging modalities is compared to CECT alone (63.7% vs. 93.1%, P = 0.00012) and 
      (68)Ga-DOTA-NOC/TATE PET/CT alone (74.1% vs. 93.1%, P = 0.0057), it provided 
      significantly higher per-lesion sensitivity for the detection of 
      gastroenteropancreatic neuroendocrine tumors (GEP-NETs). (68)Ga-DOTA-NOC/ TATE 
      PET was more sensitive for the detection of gastrinomas and metastases than CECT, 
      whereas it was less sensitive for the detection of parathyroid lesions than CECT. 
      The combined use of both the imaging modalities significantly increases the 
      sensitivity for detection of GEP-NETs.
CI  - Copyright: (c) 2020 World Journal of Nuclear Medicine.
FAU - Patil, Virendra A
AU  - Patil VA
AD  - Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, 
      Maharashtra, India.
FAU - Goroshi, Manjunath R
AU  - Goroshi MR
AD  - Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, 
      Maharashtra, India.
FAU - Shah, Hina
AU  - Shah H
AD  - Department of Nuclear Medicine and Positron Emission Tomography/Computed 
      Tomography, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India.
FAU - Malhotra, Gaurav
AU  - Malhotra G
AD  - Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre, 
      Mumbai, Maharashtra, India.
FAU - Hira, Priya
AU  - Hira P
AD  - Department of Radiology, Seth GS Medical College and KEM Hospital, Mumbai, 
      Maharashtra, India.
FAU - Sarathi, Vijaya
AU  - Sarathi V
AD  - Department of Endocrinology, Narayana Medical College, Nellore, Andhra Pradesh, 
      India.
FAU - Lele, Vikram R
AU  - Lele VR
AD  - Department of Nuclear Medicine and Positron Emission Tomography/Computed 
      Tomography, Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India.
FAU - Jadhav, Swati
AU  - Jadhav S
AD  - Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, 
      Maharashtra, India.
FAU - Lila, Anurag
AU  - Lila A
AD  - Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, 
      Maharashtra, India.
FAU - Bandgar, Tushar R
AU  - Bandgar TR
AD  - Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, 
      Maharashtra, India.
FAU - Shah, Nalini S
AU  - Shah NS
AD  - Department of Endocrinology, Seth GS Medical College and KEM Hospital, Mumbai, 
      Maharashtra, India.
LA  - eng
PT  - Journal Article
DEP - 20200129
PL  - Germany
TA  - World J Nucl Med
JT  - World journal of nuclear medicine
JID - 101286955
PMC - PMC7478292
OTO - NOTNLM
OT  - 68Ga-DOTA-Nai3-octreotide/tyr3-octreotate positron emission tomography/computed 
      tomography
OT  - contrast enhanced computed tomography
OT  - gastrointestinal-pancreatic neuroendocrine tumor
OT  - multiple endocrine neoplasia type 1 imaging
OT  - multiple endocrine neoplasia type 1 syndrome
COIS- There are no conflicts of interest.
EDAT- 2020/09/18 06:00
MHDA- 2020/09/18 06:01
PMCR- 2020/01/29
CRDT- 2020/09/17 05:44
PHST- 2019/03/19 00:00 [received]
PHST- 2019/06/18 00:00 [accepted]
PHST- 2020/09/17 05:44 [entrez]
PHST- 2020/09/18 06:00 [pubmed]
PHST- 2020/09/18 06:01 [medline]
PHST- 2020/01/29 00:00 [pmc-release]
AID - WJNM-19-99 [pii]
AID - 10.4103/wjnm.WJNM_24_19 [doi]
PST - epublish
SO  - World J Nucl Med. 2020 Jan 29;19(2):99-105. doi: 10.4103/wjnm.WJNM_24_19. 
      eCollection 2020 Apr-Jun.